◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BIO

Bio-Rad Laboratories Inc (BIO) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-19

Bio-Rad Laboratories Inc (BIO) operates in the MEDICAL DEVICES industry and is headquartered in Hercules, United States with about 7,450 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, BIO reported $2.6B in revenue and $760M in net income.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.

Interactive charts & full statements → Open the BIO valuation workbench →

BIO Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$2.6B	$2.6B	$2.6B	$2.7B	$2.8B	$2.9B	$2.5B	$2.3B	$2.3B	$2.2B	$2.1B	$2.0B	$2.2B	$2.1B	$2.1B	$2.1B	$1.9B	$1.8B	$1.8B	$1.5B	$1.3B
Gross Profit	$1.3B	$1.3B	$1.4B	$1.4B	$1.6B	$1.6B	$1.4B	$1.3B	$1.2B	$1.2B	$1.1B	$1.1B	$1.2B	$1.2B	$1.2B	$1.2B	$1.1B	$1.0B	$963M	$791M	$713M
Gross Margin %	51.9%	52.0%	53.7%	53.4%	55.9%	56.0%	56.5%	54.4%	53.5%	55.0%	55.0%	55.5%	54.2%	55.3%	56.1%	56.8%	56.6%	56.0%	54.5%	54.2%	55.9%
Operating Income (EBIT)	$235M	$270M	$269M	$338M	$483M	$500M	$421M	$230M	($109M)	$117M	$53M	$167M	$150M	$169M	$264M	$295M	$284M	$231M	$183M	$135M	$146M
Operating Margin %	9.1%	10.5%	10.5%	12.7%	17.2%	17.1%	16.6%	9.9%	-4.7%	5.4%	2.6%	8.3%	6.9%	8.0%	12.8%	14.2%	14.7%	13.0%	10.4%	9.2%	11.5%
Net Income	$222M	$760M	($1.8B)	($637M)	($3.6B)	$4.3B	$3.8B	$1.8B	$361M	$115M	$28M	$113M	$89M	$78M	$169M	$178M	$185M	$145M	$90M	$93M	$103M
Net Margin %	8.6%	29.4%	-71.9%	-23.9%	-129.4%	145.6%	149.8%	76.1%	15.8%	5.3%	1.4%	5.6%	4.1%	3.6%	8.2%	8.6%	9.6%	8.1%	5.1%	6.4%	8.1%
EBITDA	—	$1.2B	($2.1B)	($655M)	($4.5B)	$5.6B	$5.1B	$2.5B	$675M	$270M	$206M	$299M	$304M	$305M	$404M	$410M	$393M	$335M	$272M	$220M	$229M
Earnings Per Share (EPS)	$8.25	$27.85	$-65.36	$-21.82	$-121.79	$140.83	$126.47	$58.27	$11.94	$3.82	$0.95	$3.85	$3.05	$2.69	$5.91	$6.26	$6.59	$5.20	$3.24	$3.41	$3.83
Shares Outstanding (M)	—	27M	28M	29M	30M	30M	30M	30M	30M	30M	30M	29M	29M	29M	29M	28M	28M	28M	28M	27M	27M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$651M	$592M	$693M	$653M	$652M	$585M	$667M	$650M	$638M
Gross Profit	$346M	$309M	$345M	$343M	$345M	$306M	$342M	$356M	$355M
Gross Margin %	53.1%	52.2%	49.8%	52.6%	53.0%	52.3%	51.2%	54.8%	55.6%
Operating Income (EBIT)	$73M	$34M	$62M	$66M	$77M	$24M	$58M	$64M	$101M
Operating Margin %	11.2%	5.8%	8.9%	10.2%	11.8%	4.0%	8.7%	9.9%	15.9%
Net Income	$371M	($527M)	$720M	($342M)	$318M	$64M	($716M)	$653M	($2.2B)
Net Margin %	57.0%	-89.0%	103.9%	-52.4%	48.8%	10.9%	-107.2%	100.5%	-339.2%
EBITDA	—	($637M)	$994M	($365M)	$477M	$134M	($847M)	$923M	($2.7B)
Earnings Per Share (EPS)	$13.85	$-19.55	$26.65	$-12.70	$11.67	$2.29	$-25.57	$23.34	$-76.26
Shares Outstanding (M)	—	27M	27M	27M	27M	28M	28M	28M	28M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIO Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$493M	$532M	$455M	$375M	$194M	$657M	$585M	$458M	$285M	$104M	$216M	$186M	$273M	$169M	$266M	$263M	$226M	$325M	$191M	$192M	$118M
Capital Expenditures (CapEx)	$140M	$158M	$189M	$157M	$114M	$121M	$109M	$99M	$130M	$115M	$142M	$113M	$136M	$107M	$145M	$103M	$93M	$76M	$89M	$63M	$53M
Free Cash Flow (FCF)	$353M	$375M	$266M	$218M	$80M	$536M	$476M	$359M	$156M	($11M)	$74M	$73M	$137M	$62M	$122M	$159M	$133M	$249M	$103M	$129M	$65M
FCF Margin %	13.6%	14.5%	10.4%	8.2%	2.9%	18.3%	18.7%	15.6%	6.8%	-0.5%	3.6%	3.6%	6.3%	2.9%	5.9%	7.7%	6.9%	13.9%	5.8%	8.8%	5.1%
Dividends Paid	—	—	—	$100.1B	$68.2B	$35.3B	$20M	$3.8B	—	$4M	—	$0M	$0M	$0M	$11M	$0M	$0M	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIO Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$99M	$108M	$165M	$121M	$116M	$130M	$124M	$164M	$98M
Capital Expenditures (CapEx)	$32M	$30M	$46M	$32M	$46M	$34M	$43M	$64M	$42M
Free Cash Flow (FCF)	$67M	$78M	$119M	$89M	$71M	$96M	$81M	$100M	$55M
FCF Margin %	10.3%	13.2%	17.2%	13.7%	10.9%	16.3%	12.2%	15.4%	8.7%
Dividends Paid	—	$33M	—	$63M	$49M	—	—	$16M	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BIO Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$10.3B	$10.6B	$9.4B	$12.3B	$13.5B	$17.8B	$13.0B	$8.0B	$5.6B	$4.3B	$3.9B	$3.7B	$3.3B	$3.4B	$3.4B	$3.1B	$3.1B	$2.5B	$2.0B	$2.0B	$1.6B
Cash & Cash Equivalents	$517M	$532M	$488M	$404M	$434M	$471M	$662M	$661M	$432M	$384M	$456M	$458M	$413M	$332M	$463M	$574M	$907M	$650M	$205M	$162M	$224M
Total Liabilities	$3.1B	$3.1B	$2.8B	$3.6B	$3.9B	$4.1B	$3.1B	$2.3B	$1.6B	$1.3B	$1.3B	$1.2B	$1.2B	$1.2B	$1.4B	$1.4B	$1.5B	$1.3B	$967M	$1.0B	$777M
Total Debt (Short + Long-Term)	$1.4B	$1.2B	$1.2B	$1.2B	$1.2B	$47M	$51M	$475M	$439M	$435M	$435M	$434M	$436M	$437M	$734M	$733M	$964M	$743M	$456M	$457M	$429M
Total Shareholders' Equity	$7.2B	$7.5B	$6.6B	$8.7B	$9.6B	$13.7B	$9.9B	$5.8B	$4.0B	$2.9B	$2.6B	$2.5B	$2.2B	$2.2B	$2.0B	$1.7B	$1.5B	$1.3B	$1.0B	$972M	$820M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BIO viewer.

BIO Metric Deep Dives

Other Companies in MEDICAL DEVICES

PHG · Koninklijke Philips NV ADR — $24 billion
PEN · Penumbra Inc — $13 billion
SNN · Smith & Nephew SNATS Inc — $12 billion
GMED · Globus Medical — $10 billion
BIO.B · Bio-Rad Laboratories Inc — $10 billion
GKOS · Glaukos Corp — $10 billion
BRKR · Bruker Corporation — $9 billion
HAE · Haemonetics Corporation — $5 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← BINV All “B” companies BIO.B →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.